GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

This study is testing a new CAR-T cell therapy called GPC2-CAR T cells — where a patient's own immune cells are genetically modified to target and destroy brain tumor cells — in children and young adults with medulloblastoma or related rare brain tumors (embryonal tumors) that have returned or progressed after prior treatment. **You may be eligible if...** - You have been diagnosed with medulloblastoma or another related embryonal brain tumor, confirmed by biopsy - Your tumor has come back or progressed after initial treatment with curative intent - You are typically under 30 years old (pediatric and young adult patients) - Your cancer cells test positive for the GPC2 protein target **You may NOT be eligible if...** - You have not had any prior treatment for the tumor - You have serious organ dysfunction (heart, liver, kidney, or lung) - You have active serious infections - Your overall health is too poor for intensive treatment Talk to your doctor to see if this trial is right for you.